Clinical Trial ProgressBuntanetap pivotal trial in Alzheimer's disease completed with enrollment exceeding its original target, and a very low dropout rate, indicating robust participation and data.
Drug Safety ProfileDuring the safety analysis, no drug-related serious adverse events were reported for buntanetap and adverse events were less than 5%, suggesting a favorable safety profile.
Investment AnalysisAnalyst reiterates a Buy rating with a 12-month target based on discounted cash flow valuation methodology, signaling a positive investment outlook.